Literature DB >> 25134466

Brain-targeted delivery of docetaxel by glutathione-coated nanoparticles for brain cancer.

Aditya Grover1, Anjali Hirani, Yashwant Pathak, Vijaykumar Sutariya.   

Abstract

Gliomas are some of the most aggressive types of cancers but the blood-brain barrier acts as an obstacle to therapeutic intervention in brain-related diseases. The blood-brain barrier blocks the permeation of potentially toxic compounds into neural tissue through the interactions of brain endothelial cells with glial cells (astrocytes and pericytes) which induce the formation of tight junctions in endothelial cells lining the blood capillaries. In the present study, we characterize a glutathione-coated docetaxel-loaded PEG-PLGA nanoparticle, show its in vitro drug release data along with cytotoxicity data in C6 and RG2 cells, and investigate its trans-blood-brain barrier permeation through the establishment of a Transwell cellular co-culture. We show that the docetaxel-loaded nanoparticle's size enables its trans-blood-brain barrier permeation; the nanoparticle exhibits a steady, sustained release of docetaxel; the drug is able to induce cell death in glioma models; and the glutathione-coated nanoparticle is able to permeate through the Transwell in vitro blood-brain barrier model.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 25134466      PMCID: PMC4245440          DOI: 10.1208/s12249-014-0165-0

Source DB:  PubMed          Journal:  AAPS PharmSciTech        ISSN: 1530-9932            Impact factor:   3.246


  27 in total

1.  In vitro model for evaluating drug transport across the blood-brain barrier.

Authors: 
Journal:  Adv Drug Deliv Rev       Date:  1999-04-05       Impact factor: 15.470

Review 2.  Opsonization, biodistribution, and pharmacokinetics of polymeric nanoparticles.

Authors:  Donald E Owens; Nicholas A Peppas
Journal:  Int J Pharm       Date:  2005-11-21       Impact factor: 5.875

3.  Development of a three-dimensional, all-human in vitro model of the blood-brain barrier using mono-, co-, and tri-cultivation Transwell models.

Authors:  Kathryn Hatherell; Pierre-Olivier Couraud; Ignacio A Romero; Babette Weksler; Geoffrey J Pilkington
Journal:  J Neurosci Methods       Date:  2011-05-14       Impact factor: 2.390

Review 4.  Analytical and biological methods for probing the blood-brain barrier.

Authors:  Courtney D Kuhnline Sloan; Pradyot Nandi; Thomas H Linz; Jane V Aldrich; Kenneth L Audus; Susan M Lunte
Journal:  Annu Rev Anal Chem (Palo Alto Calif)       Date:  2012       Impact factor: 10.745

Review 5.  The role of amino acid transporters in GSH synthesis in the blood-brain barrier and central nervous system.

Authors:  Cesar Valdovinos-Flores; María E Gonsebatt
Journal:  Neurochem Int       Date:  2012-05-24       Impact factor: 3.921

6.  Differentiated rat glial cell strain in tissue culture.

Authors:  P Benda; J Lightbody; G Sato; L Levine; W Sweet
Journal:  Science       Date:  1968-07-26       Impact factor: 47.728

7.  Narciclasine, a plant growth modulator, activates Rho and stress fibers in glioblastoma cells.

Authors:  Florence Lefranc; Sébastien Sauvage; Gwendoline Van Goietsenoven; Véronique Mégalizzi; Delphine Lamoral-Theys; Olivier Debeir; Sabine Spiegl-Kreinecker; Walter Berger; Véronique Mathieu; Christine Decaestecker; Robert Kiss
Journal:  Mol Cancer Ther       Date:  2009-06-16       Impact factor: 6.261

8.  Endothelial cell-astrocyte interactions and TGF beta are required for induction of blood-neural barrier properties.

Authors:  Claudia M Garcia; Diane C Darland; Lauren J Massingham; Patricia A D'Amore
Journal:  Brain Res Dev Brain Res       Date:  2004-08-18

9.  Design and potential application of PEGylated gold nanoparticles with size-dependent permeation through brain microvasculature.

Authors:  Arnold B Etame; Christian A Smith; Warren C W Chan; James T Rutka
Journal:  Nanomedicine       Date:  2011-05-04       Impact factor: 5.307

Review 10.  Update on taxane development: new analogs and new formulations.

Authors:  Jean A Yared; Katherine H R Tkaczuk
Journal:  Drug Des Devel Ther       Date:  2012-12-11       Impact factor: 4.162

View more
  14 in total

Review 1.  Strategies to target drugs to gliomas and CNS metastases of solid tumors.

Authors:  B Milojkovic Kerklaan; O van Tellingen; A D R Huitema; J H Beijnen; W Boogerd; J H M Schellens; D Brandsma
Journal:  J Neurol       Date:  2015-10-17       Impact factor: 4.849

2.  Translational application of nano delivery systems: emerging cancer therapy.

Authors:  Mahavir B Chougule; Chalet Tan
Journal:  AAPS PharmSciTech       Date:  2014-12-31       Impact factor: 3.246

Review 3.  Neurotheranostics as personalized medicines.

Authors:  Bhavesh D Kevadiya; Brendan M Ottemann; Midhun Ben Thomas; Insiya Mukadam; Saumya Nigam; JoEllyn McMillan; Santhi Gorantla; Tatiana K Bronich; Benson Edagwa; Howard E Gendelman
Journal:  Adv Drug Deliv Rev       Date:  2018-10-26       Impact factor: 15.470

Review 4.  Challenges and opportunities to penetrate the blood-brain barrier for brain cancer therapy.

Authors:  Dannielle H Upton; Caitlin Ung; Sandra M George; Maria Tsoli; Maria Kavallaris; David S Ziegler
Journal:  Theranostics       Date:  2022-06-06       Impact factor: 11.600

Review 5.  Development of Polymeric Nanoparticles for Blood-Brain Barrier Transfer-Strategies and Challenges.

Authors:  Weisen Zhang; Ami Mehta; Ziqiu Tong; Lars Esser; Nicolas H Voelcker
Journal:  Adv Sci (Weinh)       Date:  2021-03-07       Impact factor: 16.806

Review 6.  Central nervous system toxicity of metallic nanoparticles.

Authors:  Xiaoli Feng; Aijie Chen; Yanli Zhang; Jianfeng Wang; Longquan Shao; Limin Wei
Journal:  Int J Nanomedicine       Date:  2015-07-03

7.  Enhancing Anticancer Effect of Gefitinib across the Blood-Brain Barrier Model Using Liposomes Modified with One α-Helical Cell-Penetrating Peptide or Glutathione and Tween 80.

Authors:  Kuan-Hung Lin; Shu-Ting Hong; Hsiang-Tsui Wang; Yu-Li Lo; Anya Maan-Yuh Lin; James Chih-Hsin Yang
Journal:  Int J Mol Sci       Date:  2016-11-29       Impact factor: 5.923

8.  TRPA1-FGFR2 binding event is a regulatory oncogenic driver modulated by miRNA-142-3p.

Authors:  Jonathan Berrout; Eleni Kyriakopoulou; Lavanya Moparthi; Alexandra S Hogea; Liza Berrout; Cristina Ivan; Mihaela Lorger; John Boyle; Chris Peers; Stephen Muench; Jacobo Elies Gomez; Xin Hu; Carolyn Hurst; Thomas Hall; Sujanitha Umamaheswaran; Laura Wesley; Mihai Gagea; Michael Shires; Iain Manfield; Margaret A Knowles; Simon Davies; Klaus Suhling; Yurema Teijeiro Gonzalez; Neil Carragher; Kenneth Macleod; N Joan Abbott; George A Calin; Nikita Gamper; Peter M Zygmunt; Zahra Timsah
Journal:  Nat Commun       Date:  2017-10-16       Impact factor: 14.919

Review 9.  Nanotechnology Applications for Diffuse Intrinsic Pontine Glioma.

Authors:  Amy Lee Bredlau; Suraj Dixit; Chao Chen; Ann-Marie Broome
Journal:  Curr Neuropharmacol       Date:  2017       Impact factor: 7.363

Review 10.  Programmed cell death, redox imbalance, and cancer therapeutics.

Authors:  Xiaofeng Dai; Danjun Wang; Jianying Zhang
Journal:  Apoptosis       Date:  2021-07-08       Impact factor: 4.677

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.